Krystexxa (pegloticase) received FDA approval on [1] November 5, 2010. [2]
What is Krystexxa used for?
Krystexxa is a prescription medication used to treat chronic refractory gout in adults. [1] Gout is a form of inflammatory arthritis characterized by the deposition of monosodium urate crystals in the joints and tissues. [3] Chronic refractory gout refers to cases that have not responded to other treatments. [1]
How does Krystexxa work?
Krystexxa is an enzyme that works by breaking down uric acid in the body. [4] It is a pegylated uricase enzyme, which helps to increase its duration of action. [4] By reducing uric acid levels, Krystexxa helps to prevent the formation of urate crystals that cause gout flares. [3][4]
When does Krystexxa's patent expire?
Information on Krystexxa's patent exclusivity and potential patent expiries can be found on DrugPatentWatch.com. [5]
What are the potential risks of Krystexxa?
Krystexxa can cause serious infusion reactions, including anaphylaxis, which can be life-threatening. Patients are monitored during and after infusion for signs of these reactions. [1] Other potential side effects include gout flares, nausea, bruising, indigestion, constipation, chest pain, and infections. [1] It is important for patients to discuss all potential risks with their healthcare provider.
How is Krystexxa administered?
Krystexxa is administered as an intravenous infusion by a healthcare professional. [1]
What is the difference between Krystexxa and other gout treatments?
Krystexxa is designed for patients with chronic refractory gout, a more severe and persistent form of the disease. [1] Many other gout treatments focus on reducing uric acid production or increasing its excretion. Krystexxa, as a uricase enzyme, directly breaks down existing uric acid. [4]
Who manufactures Krystexxa?
Krystexxa is manufactured by Horizon Therapeutics. [6]
What clinical data supports Krystexxa's approval?
The FDA approval of Krystexxa was based on clinical trials demonstrating its efficacy in lowering serum uric acid levels and reducing the frequency of gout flares in patients with chronic refractory gout. [1]
What are patient concerns regarding Krystexxa?
Patients and their healthcare providers often discuss the risk of infusion reactions, including anaphylaxis, and strategies to mitigate these risks, such as premedication. [1] Managing gout flares during the initial treatment period is also a common concern. [1]
Sources:
1. Krystexxa Prescribing Information. [Link Placeholder for Prescribing Information if available and relevant]
2. [Link Placeholder for FDA Approval Announcement if available and relevant]
3. [Link Placeholder for General Gout Information if available and relevant]
4. [Link Placeholder for Mechanism of Action Information if available and relevant]
5. DrugPatentWatch.com [https://www.drugpatentwatch.com/]
6. [Link Placeholder for Horizon Therapeutics Website if available and relevant]